أعرض في EDS

Effects of access condition on substance use disorder-like phenotypes in male and female rats self-administering MDPV or cocaine.

التفاصيل البيبلوغرافية
العنوان: Effects of access condition on substance use disorder-like phenotypes in male and female rats self-administering MDPV or cocaine.
المؤلفون: Doyle MR; Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Beltran NM; Department of Psychology, University of Texas at El Paso, El Paso, TX, USA., Bushnell MSA; Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Syed M; Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Acosta V; Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Desai M; Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Rice KC; Drug Design and Synthesis Section, Molecular Targets and Medications Discovery Branch National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism - Intramural Research Program, Bethesda, MD., Serafine KM; Department of Psychology, University of Texas at El Paso, El Paso, TX, USA., Gould GG; Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Daws LC; Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.; Department of Cellular and Integrative Physiology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Collins GT; Department of Pharmacology, University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.; South Texas Veterans Health Care System, San Antonio, TX, USA.
المصدر: BioRxiv : the preprint server for biology [bioRxiv] 2024 Mar 08. Date of Electronic Publication: 2024 Mar 08.
نوع المنشور: Preprint
اللغة: English
بيانات الدورية: Country of Publication: United States NLM ID: 101680187 Publication Model: Electronic Cited Medium: Internet ISSN: 2692-8205 (Electronic) Linking ISSN: 26928205 NLM ISO Abbreviation: bioRxiv Subsets: PubMed not MEDLINE
مستخلص: Substance use disorder (SUD) is a heterogeneous disorder, where severity, symptoms, and patterns of substance use vary across individuals. Yet, when rats are allowed to self-administer drugs such as cocaine under short-access conditions, their behavior tends to be well-regulated and homogeneous in nature; though individual differences can emerge when rats are provided long- or intermittent-access to cocaine. In contrast to cocaine, significant individual differences emerge when rats are allowed to self-administer 3,4-methylenedioxypyrovalerone (MDPV), even under short-access conditions, wherein ~30% of rats rapidly transition to high levels of drug-taking. This study assessed the SUD-like phenotypes of male and female Sprague Dawley rats self-administering MDPV (0.032 mg/kg/infusion) or cocaine (0.32 mg/kg/infusion) by comparing level of drug intake, responding during periods of signaled drug unavailability, and sensitivity to footshock punishment to test the hypotheses that: (1) under short-access conditions, rats that self-administer MDPV will exhibit a more robust SUD-like phenotype than rats that self-administered cocaine; (2) female rats will have a more severe phenotype than male rats; and (3) compared to short-access, long- and intermittent-access to MDPV or cocaine self-administration will result in a more robust SUD-like phenotype. After short-access, rats that self-administered MDPV exhibited a more severe phenotype than rats that self-administered cocaine. Though long- and intermittent-access to cocaine and MDPV self-administration altered drug-taking patterns, manipulating access conditions did not systematically alter their SUD-like phenotype. Evidence from behavioral and quantitative autoradiography studies suggest that these differences are unlikely due to changes in expression levels of dopamine transporter, dopamine D 2 or D 3 receptors, or 5-HT 1B , 5-HT 2A , or 5-HT 2C receptors, though these possibilities cannot be ruled out. These results show that the phenotype exhibited by rats self-administering MDPV differs from that observed for rats self-administering cocaine, and suggests that individuals that use MDPV and/or related cathinones may be at greater risk for developing a SUD, and that short-access MDPV self-administration may provide a useful method to understand the factors that mediate the transition to problematic or disordered substance use in humans.
التعليقات: Update in: Drug Alcohol Depend. 2024 Oct 1;263:112408. doi: 10.1016/j.drugalcdep.2024.112408. (PMID: 39141975)
References: Neuropharmacology. 2021 Feb 1;183:108398. (PMID: 33181146)
J Pharmacol Exp Ther. 2016 Jan;356(1):85-95. (PMID: 26534942)
Eur J Neurosci. 2019 Aug;50(4):2663-2682. (PMID: 30968487)
Neuropsychopharmacology. 2014 Jan;39(2):311-8. (PMID: 23921256)
Nat Neurosci. 2018 Nov;21(11):1520-1529. (PMID: 30323276)
Addict Biol. 2020 Sep;25(5):e12809. (PMID: 31373148)
Neuropsychopharmacology. 2013 Jul;38(8):1460-71. (PMID: 23399948)
Biol Psychiatry. 2019 Jun 1;85(11):915-924. (PMID: 30846301)
Am J Psychiatry. 2000 Jul;157(7):1134-40. (PMID: 10873923)
Psychopharmacology (Berl). 2012 Oct;223(4):371-80. (PMID: 22592902)
Psychopharmacology (Berl). 2006 Jul;187(1):60-7. (PMID: 16598453)
Science. 2008 Jun 6;320(5881):1352-5. (PMID: 18535246)
J Psychoactive Drugs. 2014 Nov-Dec;46(5):369-78. (PMID: 25364987)
Addict Biol. 2019 Jul;24(4):641-651. (PMID: 29920865)
J Chem Neuroanat. 2000 Dec;20(3-4):271-80. (PMID: 11207425)
J Pharmacol Exp Ther. 2017 Apr;361(1):181-189. (PMID: 28179474)
Am J Psychiatry. 2009 Oct;166(10):1170-7. (PMID: 19723785)
J Pharmacol Exp Ther. 1994 Dec;271(3):1678-85. (PMID: 7996484)
J Neurosci. 1996 Oct 1;16(19):6100-6. (PMID: 8815892)
Psychopharmacology (Berl). 2008 Jan;195(4):591-603. (PMID: 17899015)
Science. 1998 Oct 9;282(5387):298-300. (PMID: 9765157)
Br J Pharmacol. 2013 Jan;168(2):458-70. (PMID: 22897747)
J Neurosci. 2001 Apr 15;21(8):2799-807. (PMID: 11306632)
PLoS One. 2013 Nov 04;8(11):e78258. (PMID: 24223783)
J Pharmacol Exp Ther. 2023 Mar;384(3):353-362. (PMID: 36627204)
Eur J Neurosci. 2019 Aug;50(3):2602-2612. (PMID: 30240516)
Psychopharmacology (Berl). 2021 Mar;238(3):811-823. (PMID: 33241478)
Biol Psychiatry. 2020 Nov 15;88(10):767-776. (PMID: 32312578)
Neuropsychopharmacology. 2020 Jul;45(8):1251-1262. (PMID: 31747681)
J Neurosci. 2009 Apr 15;29(15):4846-57. (PMID: 19369553)
Neuropsychopharmacology. 2013 Sep;38(10):1963-73. (PMID: 23632436)
Am J Psychiatry. 1998 Jun;155(6):832-4. (PMID: 9619159)
Neuropsychopharmacology. 2012 Apr;37(5):1092-103. (PMID: 21993206)
Biol Psychiatry. 2016 Nov 1;80(9):702-710. (PMID: 27059874)
Drug Alcohol Depend. 2004 Jun 11;74(3):265-72. (PMID: 15194204)
Nat Neurosci. 2023 Nov;26(11):1868-1879. (PMID: 37798411)
Biol Psychiatry. 2014 Nov 15;76(10):816-22. (PMID: 24433854)
J Neurosci. 1996 Dec 1;16(23):7670-7. (PMID: 8922423)
J Subst Abuse Treat. 2019 Nov;106:65-72. (PMID: 31540613)
J Pharmacol Exp Ther. 2021 Nov;379(2):108-116. (PMID: 34413199)
Neuropsychopharmacology. 2005 May;30(5):927-35. (PMID: 15647749)
Science. 2004 Aug 13;305(5686):1017-9. (PMID: 15310907)
Neuropsychopharmacology. 2008 Jan;33(2):219-25. (PMID: 17443127)
Psychopharmacology (Berl). 2019 Apr;236(4):1145-1157. (PMID: 30820634)
Neuropsychopharmacology. 2014 Jan;39(2):370-82. (PMID: 23939424)
Psychopharmacology (Berl). 2011 Jun;215(4):609-20. (PMID: 21207013)
Brain Res Mol Brain Res. 1999 Nov 10;73(1-2):181-5. (PMID: 10581411)
Neuropsychopharmacology. 2012 Jul;37(8):1901-10. (PMID: 22453139)
Eur J Neurosci. 2012 Mar;35(5):775-83. (PMID: 22304754)
Am J Psychiatry. 2001 Dec;158(12):2015-21. (PMID: 11729018)
Neuropsychopharmacology. 2004 Aug;29(8):1479-87. (PMID: 15100700)
Synapse. 1998 Sep;30(1):88-96. (PMID: 9704885)
Neuropsychopharmacology. 2011 Feb;36(3):569-79. (PMID: 20980989)
Arch Gen Psychiatry. 1989 Feb;46(2):122-6. (PMID: 2913971)
Psychopharmacology (Berl). 2021 Mar;238(3):735-744. (PMID: 33236170)
Psychopharmacology (Berl). 2014 Jul;231(13):2661-70. (PMID: 24464528)
Neuroscience. 2020 Aug 21;442:314-328. (PMID: 32682656)
Psychopharmacology (Berl). 2016 Oct;233(19-20):3587-602. (PMID: 27481050)
Neuropsychopharmacology. 2013 Mar;38(4):552-62. (PMID: 23072836)
Cold Spring Harb Perspect Med. 2012 Nov 01;2(11):. (PMID: 23125204)
Psychopharmacology (Berl). 2024 Feb 7;:. (PMID: 38326505)
Science. 2007 Mar 2;315(5816):1267-70. (PMID: 17332411)
Drug Alcohol Depend. 2014 Dec 1;145:156-67. (PMID: 25457739)
Am J Drug Alcohol Abuse. 2001 May;27(2):193-202. (PMID: 11417935)
Drug Alcohol Depend. 2014 Jun 1;139:100-5. (PMID: 24717909)
Addict Biol. 2022 May;27(3):e13168. (PMID: 35470552)
Pharmacol Rep. 2015 Jun;67(3):451-9. (PMID: 25933953)
Drug Alcohol Depend. 2008 Jan 1;92(1-3):208-16. (PMID: 17900822)
Science. 2004 Aug 13;305(5686):1014-7. (PMID: 15310906)
Synapse. 1993 Jun;14(2):169-77. (PMID: 8101394)
Neuropsychopharmacology. 2011 Dec;36(13):2741-9. (PMID: 21849981)
Obesity (Silver Spring). 2020 Oct;28(10):1964-1973. (PMID: 32860487)
Psychopharmacology (Berl). 2015 Apr;232(7):1197-205. (PMID: 25281225)
Psychopharmacology (Berl). 2020 Oct;237(10):2929-2941. (PMID: 32556402)
Addict Biol. 2021 Mar;26(2):e12904. (PMID: 32237282)
Psychopharmacology (Berl). 2005 Jun;180(1):169-76. (PMID: 15682303)
Biol Psychiatry. 2009 May 15;65(10):863-8. (PMID: 18639867)
Neuropsychopharmacology. 2018 Nov;43(12):2399-2407. (PMID: 30305739)
Neuropsychopharmacology. 2002 Jul;27(1):35-46. (PMID: 12062905)
Biol Psychiatry. 2014 Nov 15;76(10):810-5. (PMID: 24629536)
Biol Psychiatry. 2012 Sep 1;72(5):414-21. (PMID: 22503110)
Brain Res Mol Brain Res. 1997 May;45(2):335-9. (PMID: 9149110)
Neuroscience. 2010 Aug 11;169(1):182-94. (PMID: 20435100)
Neuropsychopharmacology. 2012 Jul;37(8):1816-24. (PMID: 22434223)
Psychopharmacology (Berl). 2015 Jan;232(1):125-34. (PMID: 24952093)
Learn Behav. 2022 Dec;50(4):509-523. (PMID: 35132517)
Eur Neuropsychopharmacol. 2008 Apr;18(4):303-11. (PMID: 17920248)
Psychopharmacology (Berl). 2019 Feb;236(2):625-639. (PMID: 30368583)
J Nerv Ment Dis. 1996 Oct;184(10):616-22. (PMID: 8917159)
Psychopharmacology (Berl). 2018 Jan;235(1):317-328. (PMID: 29085961)
Drug Alcohol Depend. 2008 Nov 1;98(1-2):70-6. (PMID: 18565692)
eNeuro. 2021 Jun 17;8(3):. (PMID: 33875455)
Neuropsychopharmacology. 2015 Feb;40(3):728-35. (PMID: 25212486)
معلومات مُعتمدة: R21 DA046044 United States DA NIDA NIH HHS; R36 DA050955 United States DA NIDA NIH HHS; R01 DA039146 United States DA NIDA NIH HHS; T32 NS082145 United States NS NINDS NIH HHS; R01 DA055703 United States DA NIDA NIH HHS; Z01 DA000527 United States ImNIH Intramural NIH HHS
تواريخ الأحداث: Date Created: 20240318 Latest Revision: 20240909
رمز التحديث: 20240910
مُعرف محوري في PubMed: PMC10942381
DOI: 10.1101/2024.03.04.583431
PMID: 38496609
قاعدة البيانات: MEDLINE
الوصف
تدمد:2692-8205
DOI:10.1101/2024.03.04.583431